About the Authors
- Claudia Stein
-
Contributed equally to this work with: Claudia Stein, Anaïs Flore Bardet
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Anaïs Flore Bardet
-
Contributed equally to this work with: Claudia Stein, Anaïs Flore Bardet
Affiliation Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
- Guglielmo Roma
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Sebastian Bergling
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Ieuan Clay
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Alexandra Ruchti
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Claudia Agarinis
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Tobias Schmelzle
-
Affiliation Oncology, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Tewis Bouwmeester
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
- Dirk Schübeler
-
* E-mail: dirk.schubeler@fmi.ch (DS); andreas-1.bauer@novartis.com (AB)
Affiliations Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland, University of Basel, Faculty of Sciences, Basel, Switzerland
- Andreas Bauer
-
* E-mail: dirk.schubeler@fmi.ch (DS); andreas-1.bauer@novartis.com (AB)
Affiliation Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
Competing Interests
The authors of this manuscript have read the journal's policy and have the following competing interests: CS, GR, SB, IC, AR, CA, TS, TB and AB are employees of Novartis Pharmaceuticals.
Author Contributions
Conceived and designed the experiments: CS AFB DS AB. Performed the experiments: CS AR CA. Analyzed the data: AFB GR SB IC. Wrote the paper: CS AFB TB DS AB. Commented on and revised the manuscript: CS AFB GR SB IC AR CA TS TB DS AB. Supervised the project and revised the manuscript: TS TB DS AB. Supported design, data acquisition and analysis for the RNA-seq and ChIP-seq experiments: GR SB.